Real-time Automated Program for IDentification of VT Origin
Real-time Automated Program for IDentification of VT Origin
RAPID-VT Pilot is a single centre prospective cohort pilot study to assess the feasibility,
 safety and efficacy of catheter ablation of ventricular tachycardia (VT) guided by a novel
 real-time software to localize the origin of VT during the ablation procedure.
Consecutive patients with ischemic heart disease and clinical indication of VT ablation will
 undergo baseline clinical evaluation, echocardiography and cardiac CT imaging using a
 contrast-enhanced cardiac-gated method with a 64-section scanner. Trans-axial CT images
 comprising the whole heart volume will be exported in DICOM format. CT image processing will
 be performed and will be used to delineate the LV endocardial and/or epicardial geometries.
 These data will be imported into the RAPID-VT software and the 3D-electranatomical mapping
 system for image integration.

 During the VT ablation procedure, VT(s) induction will be performed. The VT(s) 12-lead ECG
 will be acquired by the RAPID-VT software and will be localized to the scar margin using the
 RAPID-VT software. Catheter ablation will be attempted at software-determined sites.

 Post procedure, patient will be followed up for a minimum of 6 months. That will include
 Remote ICD follow-up and telephone study visits. Follow-up at 6 months will include a clinic
 visit for assessment of heart failure status, ECG, ICD interrogation and changes in
 antiarrhythmic drug therapy.
Inclusion Criteria:

 -  Patients will be eligible for inclusion if they fulfilled VANISH inclusion criteria by
 having both of:

 1. Prior myocardial infarction (pathological Q waves or imaging evidence of regional
 myocardial akinesis/thinning in the absence of a non-ischemic cause)38 and

 2. One of the following VT events within the last 6 months while on Amiodarone or
 another class III or class I antiarrhythmic drug:

 A: Sustained monomorphic VT documented on 12-lead ECG or rhythm strip requiring termination
 by pharmacologic means or DC cardioversion, B: ≥3 episodes of symptomatic VT treated with
 anti-tachycardia pacing (ATP), C: ≥1 appropriate ICD shocks, D: ≥3 VT episodes within 24
 hours, separated by ≥ 5 minutes, E: sustained VT below detection rate of an ICD

 Exclusion Criteria:

 -  Patients will be excluded from the trial if they:

 1. Are unable or unwilling to provide informed consent.

 2. Have active ischemia or another reversible cause of VT (e.g. drug-induced
 arrhythmia), or had recent acute coronary syndrome requiring revascularization.

 3. Are antiarrhythmic drug-naïve.

 4. Are known to have protruding left ventricular thrombus or mechanical aortic and
 mitral valves.

 5. Have had a prior catheter ablation procedure for VT.

 6. Are in renal failure (Creatinine clearance <15 mL/min)

 7. Have NYHA Functional class IV heart failure or CCS Functional class IV angina.

 8. Have had recent ST elevation myocardial infarction (< 1 month).

 9. Are pregnant or have a systemic illness likely to limit survival to <1 year.